BridgeMD
New treatment option for Ulcerative Colitis
Official title A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.gov ID: NCT06598943
What this study is testing
What is Eltrekibart?
Eltrekibart is an investigational medicine, being studied as a potential treatment for ulcerative colitis.
Also referred to as LY3041658.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Have had an established diagnosis of UC of ≥3 months in duration before baseline.
- Have moderately to severely active UC as assessed by the UC disease activity score.
- Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication (including corticosteroids) or one...
- Are on a stable dose of certain oral UC medications (including corticosteroids).
- Must meet contraception requirements.
You likely can't join if
- Have received anti-interleukin (IL)-23p19 or anti-IL-12p40 antibodies in the past.
- Have experienced a thrombotic event within 24 weeks before baseline.
- Have a current diagnosis of Crohn's Disease or certain other inflammatory gastrointestinal diseases.
- Have had certain abdominal surgeries within the past 3 months or are likely to require surgery for UC during the study.
- Have a history of certain adenomas, dysplasia's, or malignancies.
The study team makes the final eligibility decision.
Where it's taking place
- Chandler, Arizona, United States
- Little Rock, Arkansas, United States
- Chula Vista, California, United States
- Coronado, California, United States
- Garden Grove, California, United States
- Lancaster, California, United States
- Los Alamitos, California, United States
- Orange, California, United States
- Rancho Cucamonga, California, United States
- Thousand Oaks, California, United States
- Victorville, California, United States
- Colorado Springs, Colorado, United States
- Hamden, Connecticut, United States
- Clermont, Florida, United States
- Doral, Florida, United States
- Lakewood Rch, Florida, United States
- Miami, Florida, United States
- Orange Park, Florida, United States
- Orlando, Florida, United States
- Tampa, Florida, United States
+ 151 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chandler, Arizona, United States; Little Rock, Arkansas, United States; Chula Vista, California, United States; Coronado, California, United States; Garden Grove, California, United States; Lancaster, California, United States and 165 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.